| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 405.60▼ | 408.26▼ | 409.63▼ | 326.22▲ | 327.23▲ |
| MA10 | 406.77▼ | 410.56▼ | 379.81▲ | 317.91▲ | 311.70▲ |
| MA20 | 408.35▼ | 375.14▲ | 342.79▲ | 311.90▲ | 306.02▲ |
| MA50 | 410.05▼ | 333.84▲ | 322.27▲ | 300.86▲ | 331.10▲ |
| MA100 | 389.64▲ | 321.62▲ | 316.49▲ | 300.64▲ | 297.54▲ |
| MA200 | 347.60▲ | 315.36▲ | 307.14▲ | 324.74▲ | 260.31▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.443▼ | 0.071▲ | 9.263▲ | 5.561▲ | 9.146▲ |
| RSI | 34.058▼ | 71.063▲ | 80.324▲ | 83.293▲ | 72.209▲ |
| STOCH | 8.140▼ | 22.085 | 81.742▲ | 34.453 | 70.957 |
| WILL %R | -100.000▼ | -23.149▲ | -23.137▲ | -22.834▲ | -18.746▲ |
| CCI | -119.387▼ | 0.952 | 58.268 | 466.667▲ | 389.675▲ |
| ▲ PSAR&MOM | $UTHR PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI&MACD | $UTHR MACD cross and RSI above 55 | Set Alert |
| ▲ RSI | $UTHR RSI(14) Crossed Above 70 | Set Alert |
| ▲ MACD | $UTHR MACD(12,26,9) Crossed Above Signal Line | Set Alert |
| MA | $UTHR Price Crossed Above MA(200) | Set Alert |
| MA | $UTHR Price Crossed Above MA(13) | Set Alert |
| MA | $UTHR Price Crossed Above MA(7) | Set Alert |
| ▲ GAP | $UTHR Open Gap Up %5 | Set Alert |
| ▲ GAP | $UTHR Open Gap Up %3 | Set Alert |
| ▲ GAP | $UTHR Open Gap Up %2 | Set Alert |
| ▲ BREAK | $UTHR Price Breaks 60 Days High | Set Alert |
| ▲ BREAK | $UTHR Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $UTHR Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $UTHR Price Breaks 10 Days High | Set Alert |
|
Tuesday, September 02, 2025 08:33 AM
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.
|
|
Tuesday, September 02, 2025 08:06 AM
United Therapeutics shares surged after its lung therapy Tyvaso met the main goal in a late-stage IPF trial, highlighting strong market potential, financial strength, and upcoming FDA discussions.
|
|
Tuesday, September 02, 2025 04:54 AM
Investing.com -- United Therapeutics (NASDAQ:UTHR) stock rose 54% after the company announced that its TETON-2 pivotal study of Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/09/25 | 418.87 | 435.09 | 403.21 | 404.54 | 2,720,072 |
| 29/08/25 | 307.16 | 307.985 | 303.085 | 304.76 | 418,774 |
| 28/08/25 | 305.57 | 309.00 | 302.19 | 307.24 | 749,916 |
| 27/08/25 | 308.02 | 312.44 | 305.03 | 305.345 | 583,475 |
| 26/08/25 | 306.76 | 309.34 | 304.475 | 309.22 | 1,305,685 |
| 25/08/25 | 310.72 | 312.6451 | 304.84 | 305.38 | 659,907 |
| 22/08/25 | 310.00 | 315.73 | 308.26 | 312.23 | 576,485 |
| 21/08/25 | 303.59 | 311.37 | 303.59 | 310.66 | 546,939 |
| 20/08/25 | 313.22 | 314.98 | 306.01 | 306.48 | 685,044 |
| 19/08/25 | 314.10 | 317.31 | 311.355 | 313.22 | 595,028 |
|
|
||||
|
|
||||
|
|